Hemophilia B - Pipeline Review, H2 2018

September 2018 | 135 pages | ID: H53B1CA925BEN
Global Markets Direct

Abstracts

Hemophilia B - Pipeline Review, H2 2018

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hemophilia B - Pipeline Review, H2 2018, provides an overview of the Hemophilia B (Hematological Disorders) pipeline landscape.

Hemophilia B is a hereditary bleeding disorder caused by a lack of blood clotting factor IX. Symptoms include bleeding into joints and associated pain and swelling, bruising, excessive bleeding following circumcision, gastrointestinal tract and urinary tract hemorrhage and nosebleeds. Treatment includes replacing the defective clotting factor.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hemophilia B - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Hemophilia B (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hemophilia B (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hemophilia B and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 6, 10, 1, 10, 1 and 1 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 2, 3 and 1 molecules, respectively.

Hemophilia B (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Hemophilia B (Hematological Disorders).
• The pipeline guide reviews pipeline therapeutics for Hemophilia B (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Hemophilia B (Hematological Disorders) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Hemophilia B (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Hemophilia B (Hematological Disorders)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Hemophilia B (Hematological Disorders).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Hemophilia B (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Hemophilia B - Overview
Hemophilia B - Therapeutics Development
Hemophilia B - Therapeutics Assessment
Hemophilia B - Companies Involved in Therapeutics Development
Hemophilia B - Drug Profiles
Hemophilia B - Dormant Projects
Hemophilia B - Discontinued Products
Hemophilia B - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Hemophilia B, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Products under Development by Companies, H2 2018 (Contd.2), H2 2018
Products under Development by Universities/Institutes, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Hemophilia B - Pipeline by Amarna Therapeutics BV, H2 2018
Hemophilia B - Pipeline by Bayer AG, H2 2018
Hemophilia B - Pipeline by Bioverativ Inc, H2 2018
Hemophilia B - Pipeline by Catalyst Biosciences Inc, H2 2018
Hemophilia B - Pipeline by China Biologic Products Inc, H2 2018
Hemophilia B - Pipeline by CSL Ltd, H2 2018
Hemophilia B - Pipeline by Expression Therapeutics LLC, H2 2018
Hemophilia B - Pipeline by GC Pharma, H2 2018
Hemophilia B - Pipeline by Genethon SA, H2 2018
Hemophilia B - Pipeline by LFB SA, H2 2018
Hemophilia B - Pipeline by Logicbio Therapeutics Inc, H2 2018
Hemophilia B - Pipeline by Novo Nordisk AS, H2 2018
Hemophilia B - Pipeline by OPKO Biologics Ltd, H2 2018
Hemophilia B - Pipeline by Pfizer Inc, H2 2018
Hemophilia B - Pipeline by Pharming Group NV, H2 2018
Hemophilia B - Pipeline by Promethera Biosciences SA, H2 2018
Hemophilia B - Pipeline by RegenxBio Inc, H2 2018
Hemophilia B - Pipeline by Sangamo Therapeutics Inc, H2 2018
Hemophilia B - Pipeline by Sanofi, H2 2018
Hemophilia B - Pipeline by Shire Plc, H2 2018
Hemophilia B - Pipeline by Spark Therapeutics Inc, H2 2018
Hemophilia B - Pipeline by UniQure NV, H2 2018
Hemophilia B - Dormant Projects, H2 2018
Hemophilia B - Discontinued Products, H2 2018

List Of Figures

LIST OF FIGURES

Number of Products under Development for Hemophilia B, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Number of Products by Targets, H2 2018
Number of Products by Stage and Targets, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018

COMPANIES MENTIONED

Amarna Therapeutics BV
Bayer AG
Bioverativ Inc
Catalyst Biosciences Inc
China Biologic Products Inc
CSL Ltd
Expression Therapeutics LLC
GC Pharma
Genethon SA
LFB SA
Logicbio Therapeutics Inc
Novo Nordisk AS
OPKO Biologics Ltd
Pfizer Inc
Pharming Group NV
Promethera Biosciences SA
RegenxBio Inc
Sangamo Therapeutics Inc
Sanofi
Shire Plc
Spark Therapeutics Inc
UniQure NV